Oxycontin is a drug owned by Purdue Pharma Lp. It is protected by 31 US drug patents filed from 2013 to 2024. Out of these, 22 drug patents are active and 9 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 29, 2030. Details of Oxycontin's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oxycontin's patents.

Latest Legal Activities on Oxycontin's Patents

Given below is the list of recent legal activities going on the following patents of Oxycontin.

Event	Date	Patent/Publication
Critical Events for all Patents
Expire Patent	15 Jul, 2024	US10675278
Maintenance Fee Reminder Mailed	01 Jul, 2024	US8309060
Electronic Review	07 Jun, 2024	US11964056
Payment of Maintenance Fee, 8th Year, Large Entity	22 May, 2024	US9522919 (Litigated)
Email Notification	23 Apr, 2024	US11964056
Mail Patent eGrant Notification	23 Apr, 2024	US11964056
Patent eGrant Notification	23 Apr, 2024	US11964056
Recordation of Patent eGrant	23 Apr, 2024	US11964056
Patent Issue Date Used in PTA Calculation	23 Apr, 2024	US11964056
Recordation of Patent Grant Mailed	23 Apr, 2024	US11964056

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Oxycontin and ongoing litigations to help you estimate the early arrival of Oxycontin generic.

Oxycontin's Litigations

Oxycontin has been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 27, 2018, against patent number US9492392. The petitioner Kashiv Pharma, LLC, challenged the validity or infringement of this patent, with Purdue Pharma L.P. as the respondent. Click below to track the latest information on how companies are challenging Oxycontin's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US9492393	February, 2018	Terminated-Settled	Purdue Pharma L.P.	Kashiv Pharma, LLC
US9492392	February, 2018	Terminated-Settled	Purdue Pharma L.P.	Kashiv Pharma, LLC

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Oxycontin's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Oxycontin's generic, the next section provides detailed information on ongoing and past EP oppositions related to Oxycontin patents.

Oxycontin's oppositions filed in EPO

Oxycontin has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 14, 2007, by Purdue Pharma Lp. This opposition was filed on patent number EP04763834A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP06706682A	Dec, 2017	G. L. Pharma GmbH	Revoked
EP11186168A	Oct, 2016	James Poole Limited	Opposition rejected
EP10011792A	Oct, 2015	Hoffmann Eitle	Granted and Under Opposition
EP10011792A	Oct, 2015	Setna, Rohan P.	Granted and Under Opposition
EP10011792A	Oct, 2015	James Poole Limited	Granted and Under Opposition
EP10011792A	Oct, 2015	Acino Pharma AG	Granted and Under Opposition
EP05730345A	Dec, 2011	Actavis group PTC ehf	Patent maintained as amended
EP05730345A	Dec, 2011	Acino Pharma AG	Patent maintained as amended
EP05730345A	Dec, 2011	Elend, Almut Susanne	Patent maintained as amended
EP2005006983W	Oct, 2009	Sanofi-Aventis Deutschland GmbH	Patent maintained as amended
EP2005006983W	Oct, 2009	Ypsomed AG	Patent maintained as amended
EP04763833A	Mar, 2008	Purdue Pharma LP	Opposition rejected
EP04763834A	Dec, 2007	Purdue Pharma LP	Opposition rejected

US patents provide insights into the exclusivity only within the United States, but Oxycontin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Oxycontin's family patents as well as insights into ongoing legal events on those patents.

Oxycontin's family patents

Oxycontin has patent protection in a total of 50 countries. It's US patent count contributes only to 26.1% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Oxycontin.

Full family tree

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Generic Launch

About Oxycontin

Oxycontin is a drug owned by Purdue Pharma Lp. It is used for managing moderate to severe pain that requires long-term opioid treatment when other options are inadequate. Oxycontin uses Oxycodone Hydrochloride as an active ingredient. Oxycontin was launched by Purdue Pharma Lp in 1995.